Combination Screening

Charles River has developed several relevant two-drug combination formats to be run using 47 PDX-derived cell lines. The formats include two drugs combined in a fixed ratio format or a fixed concentration format. The format used depends on the mechanism of action of the drugs or compounds, if known, and on whether these compounds are mutually exclusive or non-exclusive.

Combination studies are initially run in prescreen mode, which includes three-point concentration steps, followed by further evaluation in 5 or 10 concentration modes to obtain synergy and/or antagonism values. Alternatively, the detailed format can be applied immediately to obtain data on synergy and/or antagonism.

We have integrated the well-known Chou-Talalay method, a linear model-based combination analysis tool, and the nonlinear model-based method developed by Zhao et al. Currently, we are working on integrating Bliss independence in our combination analysis portfolio. We recommend using at least two of these tools to evaluate combinations of synergy and antagonism.

Combination layouts are also available in the 2D assay or 3D assay platforms.

You may also be interested in...

Oncology cell

Featured Story

As head of the Tumor Biology Modeling Lab, Julia Schüler, PhD, DVM, brings a breadth of experience and a plan to improve clinical success rates of our clients’ oncology discovery programs.

Webinar Replay

View our recent webinar on cost- and time-effective methods of determining the most appropriate in vivo models for your oncology preclinical program.

Syngeneic Models

Charles River offers syngeneic mouse models suitable for the evaluation of immunobiological-based therapies.

Logo screenshot

Charles River’s Entire Discovery Portfolio

Charles River offers the most comprehensive drug discovery service portfolio in the industry, supported by scientific excellence across major therapeutic areas and target classes.